Business context and reporting period
Nutanix, Inc. (Nasdaq: NTNX) filed this Form 10-K for the fiscal year ended July 31, 2023—not a standalone Q4 report. The company sells subscription-led enterprise cloud software and services for private, hybrid and multicloud environments, primarily through channel and OEM partners. It reported one operating segment and more than 24,500 end customers.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $1.863 billion | $1.581 billion |
| GAAP gross margin | 82.2% | 79.7% |
| GAAP operating loss | $207.2 million | $458.9 million |
| GAAP net loss | $254.6 million | $798.9 million |
| Non-GAAP operating income (margin) | $161.0 million (8.6%) | $(87.2) million (-5.5%) |
| Cash from operating activities | $272.4 million | $67.5 million |
| Free cash flow | $207.0 million | $18.5 million |
- Revenue grew 17.8%; subscription revenue was $1.731 billion, about 93% of revenue. Subscription billings were $1.869 billion, about 93% of total billings.
- Total billings increased 17.4% to $2.006 billion; ACV billings rose 26.5% to $956.8 million; ARR increased to $1.562 billion from $1.202 billion.
- Cash and cash equivalents were $512.9 million and short-term investments $924.5 million at year-end, totaling $1.437 billion. Current deferred revenue was $823.7 million.
- Convertible notes had $1.373 billion aggregate principal outstanding, including accrued PIK interest on the 2026 notes; their balance-sheet carrying amount, net of discounts and issuance costs, was $1.218 billion. The 2023 notes’ $145.7 million principal was repaid at maturity in January 2023.
Material changes, outlook and risks
- Revenue growth accelerated versus FY2022 (17.8% versus 13.4%); GAAP operating and net losses narrowed, while the company moved to non-GAAP operating profitability. Gross margin improved 2.5 percentage points.
- Management attributed margin improvement partly to a greater software mix and better support-cost leverage. Average contract term declined to 3.0 years from 3.2 years, reflecting the subscription and ACV-based selling transition.
- FY2023 G&A included a $71.0 million securities-class-action settlement accrual, partly offset by a $39.9 million insurance receivable; the net settlement and related legal-fee charge was $38.7 million. A final settlement hearing was scheduled for October 2023. Separate securities and derivative actions related to the software-use investigation remained at an early stage.
- The investigation found non-compliant use of third-party evaluation software and intentional misconduct by certain employees. The company corrected an immaterial understatement of prior-period expenses prospectively; the related software-usage liability was $11.2 million at year-end.
- Management and Deloitte concluded the material weakness in internal control over financial reporting was not remediated as of July 31, 2023; disclosure controls were ineffective and Deloitte issued an adverse ICFR opinion. Deloitte nevertheless issued an unqualified opinion on the financial statements. Management targeted completion of remaining remediation measures by January 31, 2024, subject to testing.
- Management said cash and investments should cover anticipated needs for at least 12 months, while noting operating and free cash flow may fluctuate. It plans to invest in growth and R&D, improve go-to-market efficiency, and continue its subscription transition. The 10-K provides no numerical FY2024 guidance. In August 2023, the board authorized up to $350 million of share repurchases; the program is discretionary and post-year-end.
- Key risks include customer spending and sales-cycle uncertainty, subscription renewals and contract-term trends, sales-force attrition and productivity, competition from public cloud and established vendors, partner and distributor concentration, hardware supply dependencies, cybersecurity, and litigation and control-remediation risks. Arrow and Tech Data represented 32% and 16% of FY2023 revenue, respectively.
Important facts for investors to verify
- Whether the material weakness was fully remediated and controls tested effectively after the filing date.
- Final approval and payment status of the $71.0 million settlement, insurance recoveries, and outcomes of the newer securities and derivative actions.
- Subscription renewal rates, ARR and ACV billings trends, and whether shorter contract terms affect billings, cash flow or revenue growth.
- Cash generation and liquidity relative to convertible-note settlement terms, dilution potential, and the share-repurchase program.
- Progress in reducing channel concentration and maintaining sales-team productivity and hardware availability.